61 filings
8-K
AKRO
Akero Therapeutics Inc
18 Mar 24
Unregistered Sales of Equity Securities
4:31pm
8-K
AKRO
Akero Therapeutics Inc
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
8-K
AKRO
Akero Therapeutics Inc
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
AKRO
Akero Therapeutics Inc
29 Feb 24
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
AKRO
Akero Therapeutics Inc
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
2h1dzjl33 7uki
13 Nov 23
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:15am
8-K
c2ku69ct
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
70gi8ju4djicubvie6z
11 Aug 23
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
6:09am
8-K
d2iyv8s ib
26 Jun 23
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
x8nlmpjmm
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
ypvb chohhvj
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
8-K
cdqgwqdxgng6s
15 May 23
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:19am
8-K
t00h0w 68jn4tg5
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
fc0ms9wqdkjj9sblq9xy
17 Mar 23
Entry into a Material Definitive Agreement
8:43am
8-K
z5ryvrg8n1q
17 Mar 23
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
7:33am
8-K
lq8ju1zdzp qia
4 Nov 22
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:22am
8-K
tdhz6o8k23ytp6y
16 Sep 22
Entry into a Material Definitive Agreement
4:02pm
8-K
cclhizes3q0movu4c9s
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
1wfwpppwieu41a1pz3o
4 Aug 22
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
4:17pm
8-K
kwuj7u8oc 95a7ryhhp
16 Jun 22
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
7:14am